Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18767370 | 0.84 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2AAK1 | |
| SCHEMBL137000 | 0.82 | HDAC6 (0.46) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL3750504 | 0.81 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL10657115 | 0.80 | CA14 (0.38) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL21651913 | 0.79 | CA12 (0.40) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL3750380 | 0.79 | TDP1 (0.43) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL3747931 | 0.78 | CA14 (0.40) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL23288787 | 0.77 | HDAC6 (0.39) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL3882477 | 0.77 | HDAC6 (0.39) | CA14HDAC6HDAC1HDAC2CPB2 | |
| SCHEMBL14396847 | 0.77 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CA14 4487/4885HDAC6 247/4885HDAC1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.